Definium Therapeutics
American clinical-stage biopharmaceutical company developing psychedelic-based treatments
MNMD Nasdaq · home listing
MMQ Frankfurt SE
MMED Cboe Canada
ISIN CA60255C8850 SEC CIK 1813814
Follow Definium Therapeutics
Weekly email: filings, results
Net income
−$51M
+24.2% vs same quarter last year
EPS, diluted
−$0.46
+41% vs same quarter last year
Operating cash flow
−$53M
−79.2% vs same quarter last year
Operating income
−$72.3M
−58.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$183.8M |
| FY24 | −$108.7M |
| FY23 | −$95.7M |
| FY22 | −$56.8M |
| FY21 | −$93M |
| FY20 | −$33.9M |
| FY19 | - |